# Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

> **NCT01536067** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Waldenström Macroglobulinemia

## Interventions

- **BIOLOGICAL:** ofatumumab
- **DRUG:** bortezomib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01536067
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2014-04
- **Final completion:** —
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** funding was withdrawn
- **Last updated:** 2016-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536067, "Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01536067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*